You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 10,517,933


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,517,933
Title:Method of treating androgen receptor negative prostate tumors and their metastases
Abstract: The invention includes a method of preventing or treating metastasis in a subject diagnosed with prostate cancer. In certain embodiments, the metastasis comprises bone cancer. In other embodiments, the subject suffers from castration-resistant prostate cancer.
Inventor(s): Fatatis; Alessandro (Penn Valley, PA), Jernigan; Danielle (Ardmore, PA), Shahriari; Kristina Susan (Philadelphia, PA), Shen; Fei (Philadelphia, PA)
Assignee: Drexel University (Philadelphia, PA)
Application Number:15/566,031
Patent Claims:1. A method of killing, or reducing the growth rate of, a prostate cancer cell that does not express androgen receptor [AR(-) PC cell], wherein the cancer cell is part of a solid tumor within a human subject, the method comprising contacting the AR(-) PC cell with a composition consisting essentially of an effective amount of an IL1.beta.-depleting agent selected from the group consisting of anakinra, XOMA-052, AMG-108, canakinumab, rilonacept, K-832, CYT-013-IL1bQb, LY-2189102, dexamethasone, interferon-gamma, pentoxifylline, and any combinations thereof, whereby the cell is killed or growth rate of the cell is reduced.

2. The method of claim 1, wherein the solid tumor comprises a prostate tumor or a bone metastasis.

3. A method of treating or reducing rate of metastasis of a AR(-) PC cell in a human subject, the method comprising administering to the subject a composition consisting essentially of a therapeutically effective amount of an IL1 .beta.-depleting agent selected from the group consisting of anakinra, XOMA-052, AMG-108, canakinumab, rilonacept, K-832, CYT-013-IL1bQb, LY-2189102, dexamethasone, interferon-gamma, pentoxifylline, and any combinations thereof, whereby metastasis of the AR(-) PC cell in the subject is treated or metastasis rate of the AR(-) PC cell in the subject is reduced.

4. The method of claim 3, wherein the metastasis comprises bone metastasis.

5. The method of claim 3, wherein the subject suffers from castration-resistant prostate cancer.

6. The method of claim 3, wherein the IL1.beta.-depleting agent is administered to the subject by an administration route selected from the group consisting of inhalational, oral, rectal, vaginal, parenteral, topical, transdermal, pulmonary, intranasal, buccal, ophthalmic, intrathecal, and any combinations thereof.

Details for Patent 10,517,933

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Swedish Orphan Biovitrum Ab (publ) KINERET anakinra Injection 103950 11/14/2001 ⤷  Try a Trial 2035-05-12
Kiniksa Pharmaceuticals (uk), Ltd. ARCALYST rilonacept For Injection 125249 02/27/2008 ⤷  Try a Trial 2035-05-12
Novartis Pharmaceuticals Corporation ILARIS canakinumab For Injection 125319 06/17/2009 ⤷  Try a Trial 2035-05-12
Novartis Pharmaceuticals Corporation ILARIS canakinumab Injection 125319 12/22/2016 ⤷  Try a Trial 2035-05-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.